160 related articles for article (PubMed ID: 37404072)
1. Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy.
Petry L; Zuckerman AD; DeClercq J; Choi L; Lynch B; Saknini M
J Manag Care Spec Pharm; 2023 Jul; 29(7):732-739. PubMed ID: 37404072
[No Abstract] [Full Text] [Related]
2. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
Khilfeh I; Guyette E; Watkins J; Danielson D; Gross D; Yeung K
J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
[TBL] [Abstract][Full Text] [Related]
3. Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies.
Zuckerman A; Crumb J; Kandah HM; Platt T; Duckworth D; Lo K; Mitchell D; Diamantides E; Streck CM; DeClercq J; Choi L; Patel R
J Manag Care Spec Pharm; 2023 Jul; 29(7):740-748. PubMed ID: 37404071
[No Abstract] [Full Text] [Related]
4. Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Bourret J; Koenig A
J Manag Care Spec Pharm; 2016 Mar; 22(3):209-18. PubMed ID: 27003550
[TBL] [Abstract][Full Text] [Related]
5. Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy.
Peter ME; Zuckerman AD; DeClercq J; Choi L; James C; Cooper K; Choi J; Nadler M; Tanner SB
J Manag Care Spec Pharm; 2021 Jul; 27(7):882-890. PubMed ID: 34185565
[No Abstract] [Full Text] [Related]
6. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
7. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence.
Stockl KM; Shin JS; Lew HC; Zakharyan A; Harada AS; Solow BK; Curtis BS
J Manag Care Pharm; 2010 Oct; 16(8):593-604. PubMed ID: 20866164
[TBL] [Abstract][Full Text] [Related]
9. Closing the Gap: Identifying Rates and Reasons for Nonadherence in a Specialty Population.
Paolella D; Cherry E; Jolly JA; DeClercq J; Choi L; Zuckerman A
J Manag Care Spec Pharm; 2019 Nov; 25(11):1282-1288. PubMed ID: 31663457
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis medication adherence in a health system specialty pharmacy.
Berger N; Peter M; DeClercq J; Choi L; Zuckerman AD
Am J Manag Care; 2020 Dec; 26(12):e380-e387. PubMed ID: 33315331
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
13. Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies.
Zuckerman AD; DeClercq J; Choi L; Cowgill N; McCarthy K; Lounsbery B; Shah R; Kehasse A; Thomas KC; Sokos L; Stutsky M; Young J; Carter J; Lach M; Wise K; Thomas TT; Ortega M; Lee J; Lewis K; Dura J; Gazda NP; Gerzenshtein L; Canfield S
Am J Health Syst Pharm; 2021 Nov; 78(23):2142-2150. PubMed ID: 34407179
[TBL] [Abstract][Full Text] [Related]
14. Primary medication nonadherence to oral oncology specialty medications.
Zuckerman AD; Shah NB; Perciavalle K; Looney B; Peter ME; DeClercq J; Moore R; Choi L; Reynolds VW
J Am Pharm Assoc (2003); 2022; 62(3):809-816.e1. PubMed ID: 35065885
[TBL] [Abstract][Full Text] [Related]
15. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature.
Salt E; Frazier SK
Orthop Nurs; 2010; 29(4):260-75. PubMed ID: 20664466
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
17. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.
van den Bemt BJ; van den Hoogen FH; Benraad B; Hekster YA; van Riel PL; van Lankveld W
J Rheumatol; 2009 Oct; 36(10):2164-70. PubMed ID: 19723906
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.
Ding Q; Shiltz D; Hossami D; Konieczny AM
Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1231-1241. PubMed ID: 36004551
[TBL] [Abstract][Full Text] [Related]
19. Adherence to Disease-Modifying Therapies at a Multiple Sclerosis Clinic: The Role of the Specialty Pharmacist.
Banks AM; Peter ME; Holder GM; Jolly JA; Markley BM; Zuckerman SL; Choi L; Nwosu S; Zuckerman AD
J Pharm Pract; 2020 Oct; 33(5):605-611. PubMed ID: 30700202
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
